Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CHBOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.62 Med: -0.53 Max: 126.23
Current: 4.25
During the past 13 years, the highest Debt-to-EBITDA Ratio of China Health Technology Group Holding Co was 126.23. The lowest was -12.62. And the median was -0.53.
CHBOF's Debt-to-EBITDA is ranked worse than 58.85% of 209
companies
in the Forest Products industry
Industry Median: 3.27
vs CHBOF: 4.25
China Health Technology Group Holding Co (OTCPK:CHBOF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China Health Technology Group Holding Co Debt-to-EBITDA Related Terms
China Health Technology Group Holding Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Health Technology Group Holding Co Debt-to-EBITDA Chart
China Health Technology Group Holding Co Annual Data
CHBOF vs SSD, UFPI, BCC: Debt-to-EBITDA Comparison
For the Lumber & Wood Production subindustry, China Health Technology Group Holding Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Technology Group Holding Co Debt-to-EBITDA vs Forest Products Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
China Health Technology Group Holding Co (CHBOF) has a Debt-to-EBITDA of 8.13 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Health Technology Group Holding Co. According to the industry distribution chart, China Health Technology Group Holding Co ranks #123 out of 209 companies in the Forest Products industry, placing it in the top 58.9%.
Is China Health Technology Group Holding Co's Debt-to-EBITDA too high?
China Health Technology Group Holding Co's current Debt-to-EBITDA is 8.13. The Forest Products industry median Debt-to-EBITDA is 3.27. China Health Technology Group Holding Co's value of 8.13 is 148.6% above this industry median. Based on the distribution chart, China Health Technology Group Holding Co ranks #123 out of 209 companies in the Forest Products industry, which is below the industry midpoint. Overall, China Health Technology Group Holding Co has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does China Health Technology Group Holding Co's Debt-to-EBITDA compare to SSD and UFPI?
According to the Forest Products industry distribution chart, China Health Technology Group Holding Co ranks #123 out of 209 companies for Debt-to-EBITDA. This places China Health Technology Group Holding Co in the lower half of its industry. The industry median Debt-to-EBITDA is 3.27. China Health Technology Group Holding Co's value of 8.13 is 148.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Forest Products company?
The median Debt-to-EBITDA among Forest Products companies is 3.27, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Health Technology Group Holding Co's current Debt-to-EBITDA of 8.13 is 148.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Health Technology Group Holding Co. For the Forest Products industry, the median Debt-to-EBITDA is 3.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Health Technology Group Holding Co's current Debt-to-EBITDA is 8.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Technology Group Holding Co stock overvalued right now?
China Health Technology Group Holding Co (CHBOF) has a current Debt-to-EBITDA of 8.13. The stock's GF Value™ is $0.05, compared to a current price of $0.03 — trading 34.1% below its estimated fair value. The current Debt-to-EBITDA is 8.13 and 148.6% above the Forest Products industry median of 3.27. China Health Technology Group Holding Co's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China Health Technology Group Holding Co (CHBOF), the current Debt-to-EBITDA is 8.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Health Technology Group Holding Co (CHBOF) Overvalued in 2026?
Based on GuruFocus' analysis, China Health Technology Group Holding Co stock appears to be undervalued.
The current stock price of $0.03 is trading 34.1% below its estimated GF Value™ of $0.05.
Key valuation signals for CHBOF:
Debt-to-EBITDA: 8.13
GF Value™: $0.05 vs. price of $0.03 (34.1% below fair value)
Industry Position: 148.6% above the Forest Products median (#123 of 209)
No single metric tells the full story. See the CHBOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Health Technology Group Holding Co Business Description
China Health Technology Group Holding Co Ltd is an investment holding company. It is engaged in the business of management of new agriculture and forestry resources in the People's Republic of China. The company has reportable segments including the Forestry business; Horny Goat Weed Business; Health products business and Ginseng Business. The forestry management business includes plantation, logging, and sale of timber-related products and the Ginseng Business includes ginseng plantation and trading of related products. The company generates a majority of its revenue from the Forestry business segment. Geographically company generates its key revenue from the PRC.
25GF Score
Get the complete analysis for CHBOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHBOF has been successfully added to your 
